Genome-guided discovery of cancer therapeutic targets

Prathyusha Konda; Simon Garinet; Eliezer M Van Allen; Srinivas R Viswanathan

doi:10.1016/j.celrep.2023.112978

Genome-guided discovery of cancer therapeutic targets

Cell Rep. 2023 Aug 29;42(8):112978. doi: 10.1016/j.celrep.2023.112978. Epub 2023 Aug 10.

Authors

Prathyusha Konda¹, Simon Garinet¹, Eliezer M Van Allen², Srinivas R Viswanathan³

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: srinivas.viswanathan@dfci.harvard.edu.

PMID: 37572322
DOI: 10.1016/j.celrep.2023.112978

Abstract

The success of precision oncology-which aims to match the right therapies to the right patients based on molecular status-is predicated on a robust pipeline of molecular targets against which therapies can be developed. Recent advances in genomics and functional genetics have enabled the unbiased discovery of novel molecular targets at scale. We summarize the promise and challenges in integrating genomic and functional genetic landscapes of cancer to establish the next generation of cancer targets.

Keywords: CP: Cancer.

Publication types

Review